Post by free air on Jul 9, 2021 1:38:42 GMT
This company has FDA approval for Alkindi sprinkles for pediatric adrenal insufficiency as well as recently approved Rezipres(however this is royalty based.) I'm just going to focus on Alkindi sprinkles. Analysts are expecting 60m USD in peak sales for Alkindi alone, the company more recently stated peak sales can be in excess of 100m USD. The company is also planning to obtain regulatory approval in Canada which rough math indicates it will be about 10% of the US market by population.
The company is expected to be cash flow positive this year. After paying off their liabilities Eton will still have 20mill USD on their balance sheet. Subtracting that from the current market cap of 138mill USD its a 108mil USD company trading at 1x peak sales. They have other medications in their pipeline that I haven't factored in so that's an added bonus.
Of note the company had a recent sell off since the end of May when the FDA rejected their dehydrated alcohol NDA(which had a 800mill USD market).
Regardless Alkindi sprinkles alone is worth getting in at these levels. Let me know what you all think!
The company is expected to be cash flow positive this year. After paying off their liabilities Eton will still have 20mill USD on their balance sheet. Subtracting that from the current market cap of 138mill USD its a 108mil USD company trading at 1x peak sales. They have other medications in their pipeline that I haven't factored in so that's an added bonus.
Of note the company had a recent sell off since the end of May when the FDA rejected their dehydrated alcohol NDA(which had a 800mill USD market).
Regardless Alkindi sprinkles alone is worth getting in at these levels. Let me know what you all think!